Double Blind, Placebo Controlled Study Assessing the Efficacy of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase of Trial: Phase II
Latest Information Update: 03 Jul 2019
At a glance
- Drugs Buparlisib (Primary) ; Paclitaxel
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms BERIL-1
- Sponsors Novartis Pharmaceuticals
- 30 Jul 2018 According to an Adlai Nortye media release, results from this study were published in the Clinical Cancer Research, June 2018.
- 24 Jun 2018 Status has been changed to discontinued.
- 28 Feb 2018 Results of biomarker analysis published in the Clinical cancer research: an official journal of the American Association for Cancer Research